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R E V I E W
High- Density Lipoprotein in Lupus: Disease Biomarkers and 
Potential Therapeutic Strategy
Sang Yeop Kim,1  Minzhi Yu,1  Emily E. Morin,1 Jukyung Kang,1 Mariana J. Kaplan,2 and 
Anna Schwendeman1
Systemic lupus erythematosus (SLE) patients exhibit accelerated development of atherosclerosis and increased 
incidents of cardiovascular disease (CVD) that cannot be explained by traditional risk factors alone. Accumulating 
evidence suggests that reduced levels of high- density lipoproteins (HDLs), along with altered HDL composition and 
function, may contribute to the accelerated atherosclerosis in SLE patients. Normally, HDLs play various atheropro-
tective roles through facilitating cholesterol efflux, inhibiting vascular inflammation, and scavenging oxidative spe-
cies. However, systemic inflammation, oxidative stress, and autoimmunity in SLE patients induce changes in HDL 
size distribution and proteomic and lipidomic signatures. These compositional changes in HDLs result in the forma-
tion of proinflammatory, dysfunctional HDL. These lupus- altered HDLs have impaired antiatherogenic function with 
reduced cholesterol efflux capacities, impaired antioxidation abilities, and diminished antiinflammatory properties. In 
fact, dysfunctional HDL may promote atherogenesis by inducing inflammation. Thus, dysfunctional HDLs could be an 
important biomarker of accelerated atherosclerosis in lupus. Additionally, HDL- targeted therapies, especially infusion 
of reconstituted HDLs, may serve as a potential therapeutic intervention for SLE patients with CVD.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune 
 syndrome with pleiotropic clinical manifestations, characterized 
by the synthesis of autoantibodies, the development of significant 
immune dysregulation, and organ damage. While life expectancy 
in SLE has improved due to the advancement of immunosuppres-
sive therapies and improved treatments for infections and renal 
disease, mortality rates remain ~3- fold higher than in the general 
population (1). Of the many causes of mortality in SLE, acceler-
ated atherosclerosis and cardiovascular disease (CVD) is recog-
nized as one of the most prevalent (2). SLE patients showed a 
higher prevalence of coronary artery disease and atherosclerosis 
compared to controls, which could not be predicted by traditional 
risk factors alone (3). Since CVD- inflicted mortality accounts for 
more than one- third of all deaths in SLE patients (4), it is clear that 
CVD continues to be a significant threat to SLE patients.
High- density lipoprotein (HDL) is the smallest lipoprotein and 
is well- known to exhibit various atheroprotective effects inde-
pendent of cholesterol mobilization, including its antioxidative, 
antiinflammatory, antithrombotic, and antiapoptotic abilities (5). 
Thus, low levels of HDL have been associated with an increased 
risk of CVD. SLE patients with accelerated atherosclerosis 
exhibit decreased levels of HDL and the development of dys-
functional HDL (6–8). Such evidence suggests that HDL is likely 
a novel target for minimizing the risk of CVD in SLE patients, and 
several studies have recently proposed and investigated HDL- 
targeted therapies as a potential therapeutic intervention in SLE 
patients with CVD. In this review, we will discuss the quantitative 
and qualitative roles of HDL under both normal conditions and 
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in patients with SLE, as well as the potential of HDL- targeted 
therapeutic interventions (Figure 1).
Structure and composition of HDLs
HDL is constantly remodeled in the bloodstream through 
interactions with other lipoproteins, enzymes, and contact 
with target cells, resulting in significant particle heterogene-
ity. HDL consists of a core of hydrophobic lipids, including 
cholesteryl esters and triglycerides, and a surface monolayer 
containing phospholipids, free cholesterol, and apolipopro-
teins. Apolipoprotein A- I (Apo A- I) is the most abundant pro-
tein associated with HDL, comprising 70% of the total HDL 
protein content (9). Apo A- I is a 28.1- kd, highly α- helical and 
amphipathic scaffold protein consisting of 243 amino acids 
that interact with lipids to ultimately define the size and shape 
of HDL species (9).
In addition to proteins, lipid species are another key compo-
nent of the overall structure of HDL. A recent lipidome analysis 
by Kontush et al revealed that more than half of the total HDL 
mass is accounted for by lipid components, the majority being 
phospholipids—accounting for 40–60% of the total lipid mass 
(10). Of these phospholipids, phosphatidylcholines are the larg-
est population, making up 33–45% of total lipid mass, and play 
critical roles in particle stability, cholesterol efflux, and molecular 
interactions with HDL- associated enzymes (10).
HDL can be classified into different subpopulations using 
various techniques. An overview of HDL classification, based 
on the publication by Rosenson et al (11), is shown in Table 1. 
Briefly, the use of density- gradient ultracentrifugation and non-
denaturing gradient gel electrophoresis can distinguish HDL 
subpopulations on the basis of density and size, respectively; 
from smallest to largest: HDL3c, HDL3b, HDL3a, HDL2a, and 
HDL2b (11). Apo A- I containing HDL subpopulations can also be 
defined on the basis of size and charge: pre–β- 1 HDL (very small, 
discoidal HDL with Apo A- I and phospholipid), α- 4 HDL (small, 
discoidal HDL with Apo A- I, phospholipid, and free cholesterol), 
α- 3 HDL (medium-sized, spherical HDL with Apo A- I, Apo A- II, 
phospholipid, free cholesterol, cholesteryl ester, and triglyceride), 
α- 2 HDL (large, spherical HDL with the same constituents as 
α- 3 HDL), and α- 1 HDL (very large, spherical HDL with the same 
constituents as α- 3 HDL but nearly no Apo A- II) (11). Using more 
sophisticated techniques, such as nuclear magnetic resonance 
(NMR), 26 different HDL subpopulations have been identified, 
but they are simply described as small, medium, and large due 
to limited measurement precision (11). Recently, an NMR- based 
clinical analyzer called Vantera was developed to measure total 
HDL particle number in clinical laboratory settings (12).
Changes in HDL composition in SLE patients
Dyslipoproteinemia. Many SLE patients have 
increased levels of very low- density lipoproteins and low- 
density lipoproteins (LDLs) and decreased levels of HDL, con-
sidered the “lupus lipoprotein pattern.” Low HDL cholesterol 
is one of the most prevalent dyslipidemia indicators observed 
in SLE patients, including pediatric populations (13–18). In a 
multiethnic US cohort study containing 546 SLE patients, 81% 
had low HDL cholesterol levels (<35 mg/dl) (17). In a recent 
Egyptian study, 45% of 221 SLE patients presented with low 
HDL cholesterol levels (<40 mg/dl) (18). In some instances, 
no significant differences in HDL cholesterol levels were found 
between SLE patients and controls, which may be explained 
by differences in the patient population (7). Nevertheless, other 
Figure 1. A brief summary of the role of high- density lipoprotein (HDL) in systemic lupus erythematosus (SLE). CVD = cardiovascular disease.
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HDL- related abnormalities were identified in those studies, 
such as reduced paraoxonase 1 (PON- 1) activity (7).
It is noteworthy that HDL cholesterol, which is routinely 
determined in clinical laboratories, is usually considered synon-
ymous to HDL particle level. However, it has been increasingly 
recognized that HDL cholesterol may not be an appropriate 
surrogate of HDL levels, since the cholesterol content of HDL 
does not correlate perfectly with the number of HDL particles 
(19). Alternatively, some studies determined HDL levels by mea-
suring Apo A- I concentrations using immunochemistry methods, 
and lower Apo A- I levels were found in SLE patients relative to 
healthy subjects (13). Recently, direct measurement of HDL par-
ticle numbers has been made possible in clinical  laboratories 
using NMR methods (12). Chung et al found that SLE patients 
had lower numbers of large HDL particles compared to healthy 
volunteers when evaluated by NMR (20). Patients with active dis-
ease have lower HDL levels (21–24), while the use of prednisone 
and hydroxychloroquine correlates with higher HDL cholesterol 
(23,25). In contrast, simvastatin and atorvastatin have not been 
found to modify HDL cholesterol levels in SLE patients (26,27).
Changes in HDL size distribution in SLE patients. 
Lupus patients have been found to have a different distribu-
tion of HDL subfractions and HDL sizes compared to healthy 
controls (Table  2). However, the reported HDL changes vary 
between individual studies, likely due to the differences in 
patient inflammatory states as well as medications  administered 
in each study to control SLE, both affecting HDL distribution. In 
Table 1. Classification of HDL*
Separation and analytical methods Very small Small Medium Large Very large
Density
Ultracentrifugation
Classification – HDL3 – HDL2 –
Range, F1.2 – 0–3.5 – 3.5–9 –
Density- gradient ultracentrifugation
Classification HDL3c HDL3b HDL3a HDL2a HDL2b
Range, gm/ml 1.15–1.17 1.13–1.15 1.11–1.13 1.09–1.11 1.06–1.09
Size
Nondenaturing gradient gel electrophoresis
Classification HDL3c HDL3b HDL3a HDL2a HDL2b
Range, nm 7.2–7.8 7.8–8.2 8.2–8.8 8.8–9.7 9.7–12.9
2- D gel electrophoresis
Classification pre–β- 1 α- 4 α- 3 α- 2 α- 1
Range, nm 5.0–6.0 7.0–7.5 8.5–8.5 9.0–9.4 10.8–11.2
NMR
Classification Small Medium Large
Range, nm – 7.3–8.2 8.2–9.4 9.4–14 –
* HDL = high- density lipoprotein; 2- D = 2- dimensional; NMR = nuclear magnetic resonance. 
Table 2. Changes in lipoprotein profile and HDL composition in SLE patients*
Author, year (ref.) Subjects HDL changes
Delgado Alves et al, 2002 (35) 32 lupus patients and 20 matched controls Decreased PON- 1 activity
Decreased HDL2
Decreased HDL3
McMahon et al, 2006 (38) 154 women with SLE Increased proinflammatory HDL
Kiss et al, 2007 (7) 37 SLE patients Decreased Apo A- I
Decreased PON- I activity




Decreased Apo A- I
Decreased HDL size
Decreased HDL2b
Increased HDL3b and HDL3c
Batuca et al, 2009 (34) 77 lupus patients Decreased PON- 1 activity
Smith et al, 2014 (39) SLE patients and healthy controls Increased oxidized Apo A- I
Marsillach et al, 2015 (60) 54 SLE patients and 25 matched healthy controls Decreased PON- 3
Gaál et al, 2016 (16) 51 SLE patients and 49 matched healthy controls Increased SAA combination
Decreased PON- I arylesterase activity
Han et al, 2016 (33) 18 SLE patients Increased SAA combination
* HDL = high- density lipoprotein; SLE = systemic lupus erythematosus; PON- 1 = paraoxonase 1; Apo A- I = apolipoprotein A- I; 
SAA = serum amyloid A. 
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addition, the analytical methodologies used to characterize HDL 
distribution differ between studies, further hindering comparison 
of the results. Hua et al reported that small HDL is less prevalent 
in SLE patients, while the overall HDL size is increased in SLE 
patients compared to healthy controls (28). Chung et al reported 
that SLE patients have a lesser proportion of large HDL; how-
ever, the overall sizes of HDL were no different between SLE 
and healthy individuals (20). Other studies have also reported 
no significant differences in HDL size between SLE patients 
and healthy controls (16). Juárez- Rojas et al reported that SLE 
patients tend to have lower proportions of HDL2b and higher 
proportions of HDL3b and HDL3c (29). Similar results were 
reported by Formiga et al, where SLE patients had higher levels 
of HDL3 cholesterol and lower levels of HDL2 cholesterol (30).
Proteomic and lipidomic changes in SLE HDL 
 composition. HDL in SLE also has abnormal proteomic fea-
tures, with changes in Apo A- I being the most noteworthy. 
In the study by Machado et al, female adolescents with SLE 
had a higher ratio of HDL cholesterol to Apo A- I compared 
to healthy controls, indicating that the HDL particles in those 
SLE patients had a lesser amount of Apo A- I (31). Juárez- 
Rojas et al reported lower Apo A- I and higher Apo E content in 
HDL particles isolated from women with SLE (29). However, in 
another study comparing 51 SLE patients to 49 healthy con-
trols, SLE patients were found to have a higher ratio of Apo 
A- I to HDL, although the overall serum Apo A- I level was lower 
(16). Similar to proteomic alterations, the lipidome of HDL is 
also compromised in the SLE setting. Juárez- Rojas et al found 
that HDL isolated from SLE patients had less cholesteryl 
ester and more triglycerides compared to healthy controls 
(29). Moreover, lipid peroxidation is enhanced in SLE patients 
due to enhanced oxidative stress that promotes a significant 
increase in the production of oxidized lipids (32). Further, Gaál 
et al (16) and Han et al (33) found that SLE patients display 
significantly increased levels of serum amyloid A (SAA) com-
pared to healthy subjects. Additionally, multiple studies con-
firmed a significant reduction in PON- 1 and PON- 3 activity in 
SLE patients (7,16,34,35). The abnormal lipoprotein profiles in 
SLE patients are summarized in Table 2.
Figure  2. Formation of dysfunctional or proinflammatory high- density lipoprotein (HDL) in systemic lupus erythematosus (SLE). In SLE, 
multiple HDL proteomic changes occur, leading to the impairment of the function of HDL. Oxidation of apolipoprotein A- I (Apo A- I) methionine 
(Met) and tyrosine (Tyr) residues by chemical and enzymatic pathways leads to reduced ability of HDL to efflux cholesterol outside the cell and 
neutralize oxidized lipids. Increased levels of serum amyloid A (SAA) cause displacement of Apo A- I on HDL and reduced cholesterol efflux and 
antiinflammatory activity. Reduced levels and activity of HDL- associated paraoxonase 1 (PON- 1) lead to the reduced antioxidant activity of HDL.
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Proinflammatory HDL. HDL exerts antiinflammatory 
functions in healthy subjects. However, in the course of inflam-
matory disease such as SLE, the composition of HDL is altered 
and its function compromised. This can lead to the transforma-
tion of HDL into a dysfunctional, proinflammatory particle with 
reduced cholesterol efflux capacity unable to perform its nor-
mal antiinflammatory and antioxidative functions (Figure 2) (36). 
Compared to normal HDL, proinflammatory HDL is characterized 
by increased SAA content, decreased Apo A- I levels, increased 
Apo A- I oxidation, and decreased PON activity (16). Increased 
SAA content in HDL results in its displacement of Apo A- I, thus, 
reducing the atheroprotective properties of HDL (37). McMahon 
et al reported that 44.7% of SLE patients had increased levels 
of proinflammatory HDL in comparison to only 4.1% of controls 
and 20.1% of rheumatoid arthritis patients (38). Their subse-
quent study identified proinflammatory HDL to be associated 
with increased carotid intima- media thickness and plaque by 
carotid ultrasound, suggesting that dysfunctional proinflamma-
tory HDL significantly contributes to the development of subclin-
ical atherosclerosis in SLE (6).
Oxidized HDL. HDL also undergoes structural changes in 
SLE due to oxidation, and it has been found that SLE patients 
have elevated levels of oxidized HDL (Figure 2) (39). Myeloper-
oxidase (MPO) is the main oxidant enzyme responsible for the 
oxidation of HDL. MPO- catalyzed oxidation converts normal 
tyrosine on Apo A- I to 3- chlorotyrosine or 3- nitrotyrosine, leading 
to oxidized HDL (40). MPO also oxidizes 3 methionine residues 
of Apo A- I, methionine 86 (Met- 86), Met- 112, and Met- 148, con-
tributing significantly to enhancing levels of oxidized Apo A- I (41). 
In SLE patients, a high concentration of serum MPO is reported, 
implying a link between increased HDL oxidation and increased 
MPO levels in this disease. Recent studies found associations 
between HDL oxidation and elevated formation of neutrophil 
extracellular traps (NETs) (39). Under normal conditions, NETs 
play an important antimicrobial role; however, in SLE, NETs are 
dysregulated. It has been shown that the degradation of NETs is 
hindered in SLE patients, resulting in aberrant elevation of NETs 
and infiltration of netting neutrophils in tissues (42).
Carlucci et al demonstrated that SLE patients present higher 
levels of low- density granulocytes (LDGs), which are one subset 
of neutrophils with enhanced NET formation capacity (43). The 
increased LDG levels are found to be associated with the impaired 
cholesterol efflux capacity of HDL isolated from lupus patients (43). 
It has been proposed that enhanced levels of NETs enhances the 
oxidant potential in SLE and leads to the externalization to the 
extracellular space of oxidant enzymes such as MPO, nitric oxide 
synthase (NOS), and NADPH oxidase (NOX), ultimately promot-
ing oxidation of HDL (Figure 3) (43,44). Data from SLE patients 
showed that MPO and NOX from NETs promoted 3- chlorotyrosine 
modification, and NOS and NOX promoted 3- nitrotyrosine modi-
fication on HDL, while inhibition of NETs decreased the oxidation 
of HDL. These observations support the notion that NETs play a 
major role in the oxidation of HDL in SLE (39).
In addition to MPO, lipid peroxidation products also mediate 
the oxidation of HDL. Studies showed that oxidized phospholip-
ids could covalently react with Apo A- I at various sites, forming 
lipid–protein adducts (45). It was also found that lipid hydroperox-
ide could chemically react with Apo A- I and Apo A- II, leading to 
the oxidation of Met residues to methionine sulfoxide (46). Since 
clinical studies have shown that lipid peroxidation is enhanced in 
SLE patients, this may also contribute to the increased oxidation 
of Apo A- I and HDL in this disease (47).
Functional changes in HDL in SLE patients
Impaired cholesterol efflux capacity. Removal of 
excess cholesterol from macrophages in the artery wall is rec-
ognized to be the key process of HDL for protection against ath-
erosclerosis and improvement of cardiovascular outcomes. This 
process, known as reverse cholesterol transport, allows translo-
cating excess cholesterol and other lipids from lipid- laden mac-
rophages in atherosclerotic lesions to the liver for elimination. The 
first and most crucial step in reverse cholesterol transport is to 
efflux cholesterol from macrophages to HDL. HDL isolated from 
SLE patients displays a 15% decrease in cholesterol efflux ability 
compared to healthy control HDL (39). The decreased choles-
terol efflux capacity of HDL purified from SLE patients has been 
found to significantly correlate with increased noncalcified coro-
nary plaque burden (43). Multiple studies have proposed that the 
reason for decreased cholesterol efflux ability of HDL in SLE is 
increased levels of SAA. As mentioned earlier, increased levels of 
SAA promote dysfunctional proinflammatory HDL with diminished 
ability to remove cholesterol from macrophages and traffic cho-
lesteryl ester to the liver (48).
Oxidation of HDL can also contribute to its reduced choles-
terol efflux capacity in SLE. HDL containing oxidized Apo A- I has 
a reduced ability to efflux cholesterol (49,50). Furthermore, when 
Met- 148 is oxidized in Apo A- I, HDL loses the ability to interact 
with lecithin- cholesterol acyltransferase, an enzyme responsi-
ble for the conversion to cholesterol ester, which is a key step 
in reverse cholesterol transport (51). Thus, the oxidation of Apo 
A- I could be a key reason for the impaired process of cholesterol 
efflux in SLE.
Reduced antiinflammatory function. In recent years, 
it has become widely accepted that HDL can directly inhibit the 
inflammation processes that lead to the development of athero-
sclerosis (52). Although the complex antiinflammatory mechanisms 
of HDL have not been fully elucidated, it has been suggested that 
several signaling pathways play a role in this process. First, HDL 
can inhibit Toll- like receptor (TLR) pathways through activation of 
the transcriptional repressor activating transcription factor 3 (ATF-
3). Activated ATF-3 is translocated into the nucleus and inhibits 
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the promotion of TLR- induced inflammatory cytokines (53). HDL 
can also inhibit NF- κB–activated cell adhesion molecule expres-
sion, thus preventing vascular inflammation (54).
In contrast to the antiinflammatory response promoted by 
healthy HDL, HDL purified from SLE patients induces a proinflam-
matory response. Smith et al reported that HDL in SLE fails to 
inhibit cytokine induction driven by TLR pathways (55). In com-
parison to macrophages exposed to healthy HDL, macrophages 
treated with SLE HDL induced activation of NF- κB and increased 
expression of tumor necrosis factor (TNF) and interleukin- 6 (IL- 
6). In addition, macrophages treated with SLE HDL had signifi-
cantly repressed ATF- 3 activation compared to control HDL or an 
untreated group, suggesting that HDL from SLE patients cannot 
inhibit TLR pathways via ATF- 3 activation.
The oxidation of HDL in SLE promotes the binding of HDL 
to the lectin- like oxidized low- density lipoprotein receptor 1, pre-
venting ATF- 3 nuclear translocation and leading to increased syn-
thesis of inflammatory cytokines (55). HDL from SLE patients was 
also found to be able to directly up- regulate monocyte platelet- 
derived growth factor receptor β and increase chemotaxis and 
TNF release (56). Another study associated the loss of antiin-
flammatory function of HDL in SLE with the increased SAA con-
tent in HDL particles. Under normal conditions, HDL can inhibit 
inflammatory responses by disrupting lipid rafts and sequestering 
plasma membrane cholesterol; however, it has been suggested 
that the SAA binding on the surface of HDL impedes the interac-
tion between HDL and cell membrane, decreasing the antiinflam-
matory role of HDL (33).
Reduced antioxidant capacity. In both the general popu-
lation and in individuals with SLE, increased oxidized LDL level is a 
well- recognized risk factor for CVD (57). Under normal conditions, 
HDL prevents LDL oxidation by scavenging reactive oxygen spe-
cies (ROS). The increased levels of oxidized HDL and oxidized Apo 
A- I in SLE reduce the ability of HDL particles to scavenge ROS. In 
addition, proinflammatory HDL in SLE may promote LDL oxidation. 
Elevated levels of oxidized LDL increase recruitment and adherence 
of monocytes to activated endothelial cells by increasing the expres-
sion of adhesion molecules and proinflammatory cytokines (58). 
These monocytes then transmigrate to the arterial intima, taking up 
oxidized LDL and eventually maturing to form foam cells.
PON enzymes also play a critical role in the antioxidant func-
tions of HDL. Among the PON enzymes, PON- 1 is the major 
antioxidant in HDL and prevents LDL from oxidation, thereby 
eliminating biologically active oxidized LDL (46). SLE patients have 
reduced PON- 1 activity (7,16,34,35,59) and this correlates with 
the loss in antioxidative function of HDL (16). While the reasons 
for the loss in PON- 1 activity are not fully understood, levels of 
Figure  3. Formation of dysfunctional high- density lipoprotein (HDL) and autoantibodies against HDL and apolipoprotein A- I (Apo A- I) in 
systemic lupus erythematosus (SLE). In SLE, abnormal elevation of neutrophil extracellular traps (NETs) is observed, leading to endothelial cell 
(EC) damage. In the presence of NETs, increased levels of myeloperoxidase (MPO), nitric oxide synthase (NOS), NADPH oxidase (NOX), and 
reactive oxygen species (ROS) are observed, causing oxidation of HDL and Apo A- I. Oxidation of Apo A- I and HDL induces the formation of 
anti- HDL and anti–Apo A- I autoantibodies. Furthermore, oxidation of Apo A- I at Met- 148 leads to conformational changes in Apo A- I, promoting 
protein misfolding, dissociation of misfolded Apo A- I from HDL, and formation of Apo A- I amyloid fibrils. This aggregated Apo A- I is more 
immunogenic, leading to a further increase in anti–Apo A- I autoantibody titers. SM = smooth muscle cell.
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various autoantibodies inversely correlate with PON- 1 activity. 
These include IgG against Apo A- I (8,16,34), HDL (34,35), and 
β2- glycoprotein I (35), suggesting that autoantibodies may con-
tribute to the decreased activity of PON- 1. In addition to PON- 1, 
PON- 3, another member of the PON enzyme family, is decreased 
in SLE patients with subclinical atherosclerosis, potentially promot-
ing the loss of the antioxidant ability of HDL in SLE (60) (Figure 2).
Formation of autoantibodies in SLE
The production of autoantibodies is the key manifestation of 
SLE. In patients affected by autoimmune disorders, highly reactive 
IgG antibodies against human Apo A- I are detected and can bind 
to both lipid- free Apo A- I as well as Apo A- I on HDL particles 
(34). It has been reported that 32.5% of patients with SLE tested 
positively for the presence of anti–Apo A- I autoantibodies in asso-
ciation with decreased levels of HDL (61). Similar studies have 
confirmed the presence of anti–Apo A- I and its association with 
higher disease activity in SLE patients (34,62,63). In comparison, 
only 1% of healthy individuals and 20% of patients with acute cor-
onary syndrome without an autoimmune disorder have detectable 
levels of anti–Apo A- I (64). The presence of anti–Apo A- I has been 
reported to reduce the activity of PON, leading to increased LDL 
oxidation (34,35). Likewise, in lupus- prone murine models, anti–
Apo A- I was associated with decreased levels of HDL cholesterol 
and PON- 1 activity (8).
We hypothesize that increased levels of anti–Apo A- I in SLE 
patients correlates with increased lipid- free Apo A- I and oxidized 
free Apo A- I. Lipid- free Apo A- I can exist in plasma via several 
pathways, either due to de novo synthesis or dissociation from 
HDL due to displacement by elevated levels of SAA. In addition, 
oxidation of Apo A- I at the Met- 148 position leads to conforma-
tional changes in the protein (65). Oxidation of Apo A- I favors 
protein misfolding from the native α- helical structure to β- sheets, 
facilitating dissociation of Apo A- I from HDL particles and initiating 
Apo A- I amyloid fibril formation (41). Thus, in SLE plasma and in 
the oxidative microenvironment associated with NETs and athero-
sclerosis, the levels of structurally modified Apo A- I are likely to 
be elevated, leading to higher levels of lipid- free misfolded protein 
(Figure 3). Indeed, in HDL isolated from SLE patients, the median 
levels of 3- nitrotyrosine and 3- chlorotyrosine were 1.9- and 120.9- 
fold higher than in HDL isolated from healthy controls (39). The 
misfolded and oxidized Apo A- I protein is likely more immuno-
genic, thus leading to higher titers of anti–Apo A- I in SLE.
Anti- HDL antibodies have recently been identified in SLE 
patients. The differences between anti- HDL antibodies and 
anti–Apo A- I antibodies remain unclear (34,61). Lipid- free Apo 
A- I–coated enzyme- linked immunosorbent assay is most com-
monly used to measure antibody titers in serum. However, in 
some instances, the entire HDL particle is used in the assay. It is 
possible that HDL used in the assay is partially oxidized and anti-
bodies present in SLE patient serum recognize either oxidized or 
partially misfolded Apo A- I that remains to be lipid- bound in HDL 
particles (66). A few studies have reported significantly elevated 
levels of anti- HDL in SLE compared to either healthy subjects or 
patients with primary antiphospholipid syndrome (67,68). High 
anti- HDL titers were associated with increased SLE disease 
activity markers and decreased PON activity, which could lead 
to loss of antioxidant and atheroprotective functions of HDL and 
promotion of atherosclerosis development (7,34,60).
Applications of HDL therapeutics
The impact of statin use to control CVD development in SLE 
patients has been examined in several clinical studies. The Lupus 
Atherosclerosis Prevention Study showed no significant difference 
in carotid intima- media thickness of carotid plaque between SLE 
patients treated with atorvastatin and those treated with placebo 
(27). However, a recent nationwide population- based cohort study 
utilizing statin therapy showed promising results, with a significant 
reduction of risk of CVD mortality by 30% in SLE patients with 
hyperlipidemia (69). In addition, short- term atorvastatin therapy 
improved endothelium- dependent vasodilation in SLE patients 
(70). Therefore, sufficiently powered long- term prospective clinical 
trials are necessary to definitively conclude whether the use of 
statins is beneficial in SLE patients.
Reconstituted HDL, nanoparticles prepared from Apo A- I 
or Apo A- I mimetic peptides following reconstitution with phos-
pholipids, have been extensively studied as an antiatherosclerosis 
therapeutic since 1984 (71). Infusions of reconstituted HDL have 
been shown to increase levels of circulating HDL, improve plasma 
cholesterol efflux capacity, inhibit the synthesis of proinflammatory 
mediators, and improve endothelial function, leading to increased 
overall atheroprotection in animal models and in clinical trials (72). 
As of today, 6 different reconstituted HDL products have been 
tested in clinical trials, including SRC- rHDL, CSL- 111, ETC- 216, 
ETC- 642, CER- 001, and CSL- 112. Two products, ETC- 216 and 
CSL- 111, were shown to reduce plaque burden in CVD patients 
as assessed by intravascular ultrasound (73,74). CSL- 112, a 
newer formulation of CSL- 111, exhibited improved clinical safety 
and cholesterol efflux capacity in healthy volunteers compared to 
CSL- 111 (75). A phase III study of 17,400 patients to explore the 
ability of CSL- 112 to reduce major adverse cardiovascular events 
in CVD patients is currently ongoing (76).
HDL therapy has also presented beneficial effects on inflam-
matory disorders such as sepsis. It can neutralize endotoxin from 
bacteria, regulate the inflammatory response in macrophages, 
and inhibit endothelial cell activation in sepsis (77). As a result, 
the infusion of CSL- 111 suppressed proinflammatory cytokine 
production, sepsis- induced hypotension, and reduced the sever-
ity of clinical symptoms (78). Similarly, L- 4F, an Apo A- I mimetic 
peptide, demonstrated a beneficial effect in studies of various 
animal sepsis models by inhibiting proinflammatory cytokine 
production, reducing sepsis- induced hypotension, protecting 
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against organ damage, and increasing the survival rate (79,80). 
Charles- Schoeman et al have proposed a possible therapy with 
Apo A- I mimetic peptides in collagen- induced arthritis, a rodent 
model of rheumatoid arthritis (81). Rats treated with combination 
therapy of Apo A- I mimetic peptides, D- 4F, and pravastatin had a 
significantly improved clinical severity score and less erosive dis-
ease compared to both rats that received noncombination treat-
ment and control groups. Levels of inflammatory cytokines and 
chemokines were notably reduced with combination therapy and 
the antiinflammatory properties of HDL were improved.
Use of Apo A- I mimetic peptides and reconstituted 
HDL in animal models of SLE. To date, very few studies have 
tested the putative benefit of HDL treatment in animal models 
of SLE. A study by Woo et al showed significant improvements 
in SLE manifestations in a murine lupus model associated with 
accelerated atherosclerosis via treatment with the Apo A- I mimetic 
peptide, L- 4F, alone or with pravastatin (82). Notably, treatment 
with L- 4F alone or with pravastatin significantly reduced IgG 
anti–double- stranded DNA (anti- dsDNA), IgG antioxidized phos-
pholipids, proteinuria, glomerulonephritis, and osteopenia. L- 4F 
also improved the antiinflammatory functions of plasma HDL 
while reducing the proinflammatory effects of LDL. In a more 
recent study by Black et al, increased levels of Apo A- I resulted in 
suppression of lymphocyte activation, IgG anti- dsDNA autoanti-
bodies, interferon- γ–secreting CD4+ Th1 cells, and follicular T 
helper cells, along with improved glomerulonephritis in a normo-
cholesterolemic murine model of SLE (83). Smith et al investigated 
whether reconstituted HDL can reverse the proinflammatory 
effects of lupus HDL by administering ETC- 642, an HDL mimetic 
composed of the Apo A- I mimetic peptide (ESP24218) and phos-
pholipid complex, in vivo to NZM2328 mice, a mouse model of 
lupus (55). Indeed, macrophages exposed to a 1:4 ratio of SLE 
HDL to ETC- 642 significantly suppressed TNF, IL- 6, and NF- κB 
activation while promoting ATF- 3 nuclear translocation, suggest-
ing that reconstituted HDL can successfully mimic the effects of 
healthy HDL. The therapy led to significant increases in ATF- 3 
expression and lowered IL- 6 levels in serum, indicating that recon-
situted HDL can also decrease cytokine synthesis.
Future directions for reconstituted HDL therapy in 
SLE patients with CVD. Underscoring the fact that dysfunc-
tional HDL may promote CVD in SLE, HDL therapy may serve 
as a potential and alternative therapeutic because it can restore 
both the quantity and quality of HDL. It is worth noting that recon-
stituted HDL and naked Apo A- I mimetic peptides used in pre-
vious studies have not been optimized for CVD prevention and 
treatment trials in SLE, as they primarily focused on maximizing 
the efficacy of cholesterol efflux. Therefore, the potential benefit 
of reconstituted HDL therapy for CVD prevention and treatment 
in SLE patients remains unclear. An advantage of reconstituted 
HDL therapy is that it can be further customized to be more dis-
ease specific. We have recently discovered that the lipid compo-
nent of HDL can significantly alter the cholesterol efflux capacity 
and antiinflammatory properties of HDL (84). Therefore, further 
investigations to understand the protective roles of reconstituted 
HDL in SLE with CVD are needed and will inform the optimi-
zation of the reconstituted HDL composition. Administration of 
optimized reconstituted HDL in SLE models would likely increase 
the level of pre–β- HDL and may restore the antiinflammatory 
functions of HDL, and reduce proinflammatory HDL and oxidized 
LDL. Improved and restored HDL may then exert its diverse 
protective mechanisms, including the reduction of inflammatory 
mediators and activation of endothelial cells, all while improving 
cholesterol efflux capacity (Figure 4). In addition, prevention of 
autoantibody recognition may be possible in reconstituted HDL 
therapy via altering protein/peptide composition. These observa-
tions suggest that HDL mimetics may serve as an effective ther-
apeutic strategy for reducing CVD risk and, potentially, disease 
activity in SLE.
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Figure  4. Reconstituted HDL (rHDL) as a putative therapeutic strategy in patients with systemic lupus erythematosus (SLE) at risk of 
cardiovascular disease (CVD). Infusion of reconstituted HDL in SLE patients may increase the level of pre–β- HDL, reduce the presence of 
inflammatory mediators and activation of endothelial cells, enhance antiinflammatory properties and activating transcription factor 3 (ATF- 3) 
activation, and facilitate cholesterol efflux capacity.
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